Short Research Article

Effects of Ascorbic Acid, Dehydroascorbic Acid and Methotrexate on Breast Cancer Cell Viability

Abstract

Aims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate (MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive oxygen species (ROS).

Study design: In-vitro method.

Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, Coleraine, BT52 1SA, United Kingdom. September 2016-2017

Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was measured by 2',7'-dichlorofluorescein diacetate assay.

Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response with 50% inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination treatment of DHA showed decreased of ROS, which was not reversed by MTX.

Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1<1.0) and enhanced cytotoxicity of the anti-folate towards MDA-MB-231 breast cancer cells. Intracellular ROS decreased with AA and DHA treatment which might be useful for reducing MTX-related oxidative stress.

Keywords: Ascorbic Acid, Dehydroascorbic Acid, Methotrexate, Breast cancer, MDA-MB-231 cells, Reactive Oxygen Species.

1. INTRODUCTION

Breast cancer is the most common cancer that affects women worldwide [1]. In the UK, 1 in 8 women may develop breast cancer in their lifetime. In 2014, estimates show that 11,433 people died from breast cancer in the UK alone [2]. Methotrexate (MTX) is an anti-folate drug developed in the late 1940s for the treatment of acute lymphocytic leukemia and other malignancies [3]. MTX cytotoxicity is linked with oxidative stress and increases of intracellular reactive oxygen species (ROS) [4]. MTX therapy also leads to a reduction in the levels of glutathione (GSH) in tissues [5], leading to changes in the redox state, which makes cells more susceptible towards ROS [4, 6, 7].

Treatment of malignancies with MTX requires a high dose therapy, and is associated with side effects [2], due to the drug not differentiating between normal and cancerous cells [6]. Rapidly dividing cells are particularly susceptible to MTX side-effects [8], resulting in hepatotoxicity, myelosupression, nephrotoxicity, gastrointestinal toxicity [2, 9].
Supplementation using folic acid or folinic acid are well known strategies for dealing with MTX toxicity [10] but may increase the chances of relapse in patients with leukemia [2]. Antioxidant supplements were found to reduce MTX toxicity linked with high ROS [5, 6, 7, 8]. There is longstanding interest in the potential anticancer effects of ascorbic acid, which is a nutrient and a well-known antioxidant [11, 12, 13, 14, 15], Vitamin C had anti-proliferative activity [13], and could enhance effects of doxorubicin, Cisplatin and Paclitaxel [14], mitoxantrone [15], and methotrexate [16, 17]. Other studies however, suggested that AA might antagonize antineoplastic drugs leading to reductions in effectiveness [18]. Moreover, AA was noted as a pro-oxidant [19] and in that case unlikely to reduce drug side effects. Aside from the studies cited above, the use of ascorbic acid (AA) and dehydroascorbic acid (DHA) to reduce MTX toxicity has not been thoroughly studied. The aim of this investigation was to, examine the effects of AA, DHA and MTX combined treatments on MDA-MB-231 breast cancer cell cytotoxicity and intracellular reactive oxygen species (ROS).

2. MATERIAL AND METHODS

2.1 Cell Culture and plating of cells

MDA-MB-231 breast cancer cells (American Type Culture Collection, UK) were cultured in Dulbecco Modified Eagle’s Medium (DMEM) (Gibco, UK) supplemented with 10% FBS (Invitrogen, UK), 1% Penicillin/Streptomycin (Penn strep) (Invitrogen, UK) and 1% non-essential amino acid (Invitrogen, UK). Culture flasks and 96 well plates were incubated at 37°C in an atmosphere of 5% CO2 (LEEC Research CO2 Incubator, LEEC Ltd., Nottingham, UK). MDA-MB-231 cells were recovered by trypsinization. The recovered cells were counted using NucleoCounter® (NC-3000, ChemoMetec, Denmark) according to the manufactures instructions. A master mix of cells was prepared to deliver 10,000 cells in a 50 µl suspension per well and these dispensed into microplates under sterile conditions (ThermoScientific, UK).

2.2 Drug treatment

A stock solution of MTX (100 mmol/l) dissolved with dimethyl sulfoxide (DMSO) was diluted 10-fold with DMEM and filter sterilized using 0.2 µm filters (Millex-HA sterile filter units; Merck Millipore Ltd, Co. Cork Ireland). The MTX solution in DMEM media was serially diluted at concentrations 0.01, 0.1, 1, 10, 100 µmol/l using DMEM. AA or DHA was first dissolved in DMEM media (2 - 20 mmol/l) and filter sterilized using 0.2 µm filters and serially diluted at concentration 0.1, 1, 10, 100, 1000 µmol/l). Sterile solutions of drugs to be tested (50 µl) were added to cells at the concentrations mentioned and incubated for 72 h at 37°C. Cell viability was measured using MTT or sulforhodamine B (SRB) assays [20, 21].

2.3. Combination drugs study

The 50% inhibitor concentration for each agent (IC50) was determined and one half of the IC50 of AA and DHA found to be approximately 1100 µmol/l (see below). Therefore, AA or DHA (1100 µmol/l) was used for combination with varying concentration of MTX. Cells were treated with MTX (0.1, 1.0, 10, 100, 1000 µmol/l) and a fixed concentration of AA or DHA at 1100 µmol/l for 72 hours and MTT and SRB assays. Cell viability results were analysed by Compusyn™ software [22, 23] to determine, the IC50 alongside of the combination index (CI), where CI <1, CI =1 or CI >1 shows, synergism, additive responses or antagonism, respectively. A combination study of DHA and MTX was also performed for the determination of reactive oxygen species (ROS) using 2', 7'- dichlorofluorescein diacetate (DCFH-DA) assay.
2.4 MTT assay and Sulforhodamine B assays for cell viability

The MTT assay was performed as described before [20] with modification. MTT (5mg per 100 ml PBS) was filter sterilized (0.2 µM filter) before use. Cells were washed three times with cold PBS (50 µl x3) leaving behind 50 µL of PBS in each well. MTT solution (20 µl) was added to each well and microplates were incubated at 37˚C for 2 h. Formazan crystals formed were dissolved by treating with 100 µl acidified isopropanol (with 0.04M HCL) for 1 h. Absorbance was read at 570 nm using a microplate reader (VERSA Max Micro plate reader; Molecular Devices, USA).

Sulforhodamine B (SRB) staining was carried out according to the method described in [21] with a few modifications. Cells were fixed with 100 µl of cold trichloroacetic acid (TCA 10% w/v) and incubated at 5°C for 30 minutes. Cells were washed four times with tap water, blot dried after each wash, and then stained with 100 µl of SRB dye (0.06% solution in 1% acetic acid) (Sigma-Aldrich, UK) at room temperature for 30 minutes. Plates were de-stained by washing with 1% acetic (100 µl x3) acid and allowed to air dry. Trizma-base solution (10 mmol/l) was added to each well (200 µl) and placed on a shaker for 5 min. Absorbance was read at 564 nm on a microplate reader.

2.5. DCFH-Da Assay

Intracellular ROS was determined using DCFH-DA assay [24]. DCFH-DA stock solution (20.5 mmol/l) was made by adding 10 mg of DCFH-DA with 1 ml of DMSO (1 ml). To make DCFH-DA working solution, 10 ml of hank salt solution was added to 25 µl of DCFH-DA stock solution in a universal container and was filter sterilised. Cells were plated to deliver 10,000 cells/well in 96 well black polystyrene plates with 50µL media per well and incubated overnight at 37˚C to allow for the adherence of cells.

For the 60 min study cells were washed once with cold 200 µl of hank salt solution, which was then pipetted out. DCFH-DA working solution (50 µl) was added to cells and incubated for 45 min at 37˚C. Cells were then rinsed once with 200 µl of culture media DMEM, Drug treatment was performed by treating cells with AA or DHA as described above (Section 2.2.) with media as control and incubated for 60 min at 37˚C. Fluorescence was read at 485 nm excitation and 520 nm emission wavelengths on a microplate reader (FLUOstar Omega, BMG Labtech, Germany). A 72-h treatment study with DHA and MTX was performed as described above except drug treatment was for 72 h. Experiments were performed on two separate occasions and each drug treatment concentration was repeated at least 6-24 times.

2.6. Statistical analysis

One-way ANOVA tests were performed using SPSS software version 23 to identify significant differences between the means of treatments groups, statistical significant differences were considered to be P value <0.05. Results are expressed as mean ± standard error.

3. RESULTS

3.1 Single drug tests using MTT assay for MDA-MB-231 breast cancer

Single drug tests were performed using MTX, AA and DHA on MDA-MB-231 breast cancer cells for 72 h and then cell viability was assessed by the MTT assay (Fig. 1). There was dose-dependent decrease in cell viability. By contrast, AA and DHA were found to be non-cytotoxic at the concentrations examined (Fig 1). The concentrations of each agent giving 50% inhibition of cell viability (IC50) were estimated from CompuSyn™ software and are shown in Table 1 (MTT assay). When using the MTT assay, there was no cytotoxicity effect for DHA even at concentrations of 10 mmol/l (data not shown).
Table 1. Dose-response parameters determined by CompuSyn™ for MTT Assay

<table>
<thead>
<tr>
<th>Treatment</th>
<th>IC50</th>
<th>m</th>
<th>r</th>
<th>Cl</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX</td>
<td>201.4</td>
<td>0.64</td>
<td>0.71</td>
<td>N/A</td>
</tr>
<tr>
<td>AA</td>
<td>5703</td>
<td>3.97</td>
<td>1</td>
<td>N/A</td>
</tr>
<tr>
<td>DHA</td>
<td>Infinite</td>
<td>0</td>
<td>-</td>
<td>N/A</td>
</tr>
<tr>
<td>AA+MTX Combo</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>0.43</td>
</tr>
<tr>
<td>DHA+MTX Combo</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>-</td>
</tr>
</tbody>
</table>

*IC50 = median dose (µmol/l), m = response slope, r = regression coefficient, Cl = combination index. Cl corresponds to treatment 3 (MTX 10 µmol/l + 1100 µmol/l AA or DHA).

3.2 Single drug tests using sulforhodamine assay for MDA-MB-231 breast

Single drug tests were performed using MTX, AA and DHA on MDA-MB-231 breast cancer cells for 72 h and with cell viability assessed by the sulforhodamine assay (Fig 2). For MTX, a significant decrease in cell viability of 39% and 54% were seen for treatment 4 and 5, respectively compared to the control (treatment 1). The highest concentrations of AA and DHA tested produced a decrease in cell viability of 14% for AA and 16% for DHA. Table 2 shows the IC50 values for MTX, AA and DHA respectively.

Table 2: Dose-response parameters determined by CompuSyn™ for SRB Assay

<table>
<thead>
<tr>
<th>Treatment</th>
<th>IC50</th>
<th>m</th>
<th>r</th>
<th>Cl</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX</td>
<td>110.5</td>
<td>0.89</td>
<td>0.88</td>
<td>N/A</td>
</tr>
<tr>
<td>AA</td>
<td>2237</td>
<td>0.86</td>
<td>0.91</td>
<td>N/A</td>
</tr>
<tr>
<td>DHA</td>
<td>2474</td>
<td>0.70</td>
<td>0.96</td>
<td>N/A</td>
</tr>
<tr>
<td>AA+MTX Combo</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>0.46</td>
</tr>
<tr>
<td>DHA+MTX Combo</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>0.91</td>
</tr>
</tbody>
</table>

*IC50 = median dose (µmol/l), m = response slope, r = regression coefficient, Cl = combination index. Cl corresponds to treatment 3 (MTX 10 µmol/l + 1100 µmol/l AA or DHA).

3.3 Combination treatment of MDA-MB-231 cells with MTX and AA or DHA

The combination index (CI) determined by CompuSyn ranged from 0.43-251 when cells viability was assay using MTT assay while, CI range 0.46-0.91 with the SRB assay (Table 2). The CI values correspond to treatments with 10 µmol/l of MTX + 1100 µmol/l AA (as seen in Fig.1 & Fig 2, treatment 3). For the MTX and DHA combination treatment monitored with the MTT assay no toxicity effect was seen in DHA, as a result no CI value could be calculated. A CI value of 0.91 was obtained for MTX and DHA combination treatment for SRB assay (Table 2), which is the middle dose treatment that contains 10 µmol/l of MTX + 1100 µmol/l DHA showing synergism (also seen in Fig. 2, treatment 3).
Fig. 1: Effect of methotrexate (MTX) treatment with MDA-MB-231 cells in combination with Ascorbic acid (AA; Top) or dehydroascorbic acid (DHA; lower panel) with cell viability determined by MTT assay. The x-axis shows treatments (1-5) with AA (0.1, 1.0, 10, 100, 1000 µmol/l), MTX (0.01, 0.1, 1.0, 10, 100 µmol/l), and combinations (0.1, 1.0, 10, 100, 1000 µmol/l MTX) + 1100 µmol/l AA in all cases. Bars with different letters (A-E) show statistical significant differences (p value <0.05). Results are expressed as mean ± standard error. Experiment were repeated on two different occasions n = 12-24 of pooled data.
3.4 CompuSyn predictions for CI over wider concentration ranges

For all combination studies, CompuSyn analysis predicted large values for CI when at low concentrations of MTX (e.g. C1 = 0.41-5000 and CI = 0.91). The significance of such large predicted CI value is not certain.
3.5 Drug effects on intracellular ROS in MDA-MB-231 cells

One-hour treatment with 1-1000 µmol/l of AA or DAH produced small changes (+/- 10%) changes in intracellular ROS with no consistent pattern (data not shown). By comparison treatment with DHA for 72 hours produced a 50% decrease of ROS compared with media only control (Fig. 3). Subsequent treatments with MTX (0.1-1000 µM) showed no significant tendency to increase the ROS above the value for the control.

![Graph showing intracellular ROS changes after treatment with various concentrations of DHA and MTX.]

**Fig 3:** Effect of dehydroascorbic acid (DHA) and methotrexate (MTX) combination treatment MDA-MB-231 intracellular ROS cells after 72 h treatment.

Cells were treated with varying concentration of MTX (0.1, 1.0, 10, 100, 1000 µmol/l) + DHA at a fixed concentration of 1100 µmol/l. Cells with no drug treatment as control (0) was used as control and cells with DHA alone 1100 µmol/l as a positive control (shaded grey). Results are expressed as mean ± standard error. Experiment were repeated on two different occasions n = 12-24 of pooled data.

4. Discussion

The efficacy of MTX for breast cancer treatment could be better improved if the toxic side effects due to ROS were eradicated. Many studies have reported the use of various antioxidants to decrease MTX toxicity due to their ability to reduce ROS [5-8, 25-27]. Other studies reported the anti-cancer ability of AA, with concentration of 0.25-1 mmol/l being able to cause toxicity in cancer cells [11, 12, 28-30]. However, AA at lower concentration was shown to act as a protector for cells, which might explain some of the conflicting results reported [14, 26]. AA was also reported to be more toxic to cancer cells compared with normal cells, though the reasons behind this selectivity is not clear [28-30]. Studies have shown the potential that AA has to reduce the side effects caused by neoplastic drugs by enhancing their cytotoxicity, resulting in lower dosage of these drugs being used for cancer treatment [14-17].

In this study, the cytotoxicity of MTX, AA and DHA were tested for each compound using MDA-MB-231 cells. The cytotoxicity of MTX was demonstrated but IC50 values that were found that proved to be higher than that of the only study (to our knowledge) that performed the analyses under very similar conditions. Kelly & Owusu-Apenten found the IC50 of MTX was 35 µmol/l after 72 h of treatment using the MTT assay in MDA-MB-231 cells, which is significantly lower than the IC50 of 201.4 µmol/l obtained in this study [31]. Other studies that reported the IC50 of MTX used drug treatments at a shorter time or/and with different cell lines. The IC50 for both AA and DHA were found to be similar using the SRB assay. To our knowledge, no previous study reported an IC50 for AA and DHA in MDA-MB-231 cells.
Frömberg et al reported the IC50 of AA and DHA in other cell lines, as 1.7 to > 60 mM (AA) or 12.7-14.9 mM (DHA) and concluded that AA demonstrated a higher therapeutic over DHA in the cell lines [13].

Investigating both AA and DHA combination with MTX was intended to shed light on the effect of two different AA forms. AA is an antioxidant and nutrient supplement. DHA is the oxidised form of AA and has antioxidant capacity [18]. Although the level of AA found in the human serum is relatively high, intracellular transportation is limited to only a few tissues. In contrast, DHA enters cells readily by the glucose transporter (GLUT1). Intracellular DHA becomes reduced and accumulates in the cell, leading to increased levels of intracellular AA. High concentrations of AA in cells works with endogenous GSH to reduce the effects of ROS [18].

Past research showed that AA may behave as a pro-oxidant at higher concentration by producing ROS, which is a possible reason for its anti-cancer ability [12, 19]. According to current results, there were synergistic interactions between AA and MTX and also DHA and MTX. The synergistic effects were observed whether cytotoxicity was monitored by the MTT assay or SRB assay. To our knowledge, this is the first study to analyse the cytotoxicity of MTX, AA and DHA using both MTT and SRB assay. IC50 values obtained using the MTT assay were approximately double the IC50 values obtained for the SRB assay. The assays measure different indices for cells viability. The MTT assay measures mitochondrial activity while SRB assay measures cell protein. The former assay is influenced by acidic pH and reducing agents such as AA [32].

Synergism was most apparent at treatment concentrations “straddling” the IC50 value for MTX (treatments 3-4, Fig. 1 &2). These findings agree with past reports [14, 15, 16]. Kurbacher et al reported that low levels (1 µmole/l) of AA had a synergistic or additive response in combination with other neoplastic drugs in MDA-MB-231 cells [14]. The concentrations of AA used were lower in comparison to the doses in this study. A recent study by Wu et al also reported a synergistic effect of AA and MTX and attributed such effects to increases of intracellular hydrogen peroxide and activation of apoptosis pathways [17].

Intracellular ROS levels were largely unchanged (+/-10% control values) after an hour treatment with AA or DHA in MDA-MB-231 cells. By comparison, 72 hr treatment with DHA showed 50% reduction in intracellular ROS, and the reduction was retained after addition of MTX (0.1-1000 µM). However, others reported that low concentrations of AA could increase ROS when combined with low doses of MTX in MDA-MB-231 cells [17].

5. CONCLUSION

Ascorbic acid and DHA were found to be cytotoxic towards MDA-MB-231 cells. Combination treatment of AA or DHA with MTX resulted in synergistic responses indicating improved effectiveness of the anti-folate drug. Analysis of intracellular ROS showed that AA or DHA co-treatment could maintain low levels of oxidative stress. Further research is required to study different combinations of AA and MTX for treatment of breast cancer.
Authors have declared that no competing interests exist.

No human subjects are involved and no content was sought.

No human subjects are involved and no content was sought.


